Page 6 - ஒன்றுபட்டது மாநிலங்களில் காரணமாக News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV Hyloris Pharmaceuticals SAApril 28, 2021 GMT Hikma Pharmaceuticals, a leading supplier of complex, injectable hospital products in the U.S., to commercialise Maxigesic IV in the U.S. Hyloris is eligible to receive $4 million in regulatory based milestones as well as commercial milestones and a share of net profit Maxigesic IV has potential to combat the opioid epidemic in pain management Liège, Belgium – 28 April 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner for Maxigesic IV, AFT Pharmaceuticals (“AFT”), has signed an exclusive license and distribution agreement with Hikma Pharmaceuticals (“Hikma”) for the U.S. commerc

Marieke vermeerschStijn van rompayCenters for diseaseDelveinsight market researchHyloris pharmaceuticalsHikma pharmaceuticalsHyloris pharmaceuticals sa euronext brusselsCorporate communicationsEuronext brusselsVan rompayChief executive officerUnited stateshikmaUnited states theUnited states dueDisease controlInsight market research report